Antitrust Antitrust

Teva, Cephalon get extra set of EU antitrust charges in pay-for-delay probe (update*)

By Michael Acton
  • 08 Jun 2020 06:18
  • 08 Jun 2020 08:09
Teva and Cephalon have received supplementary charges as part of an ongoing EU antitrust probe into the two pharmaceutical companies over suspected “pay-for-delay” agreements, the European Commission said.
The fresh set of charges follows an initial statement of objections sent to the companies in July 2017. 

The EU regulator

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Michael Acton

Senior Correspondent

Michael is a senior correspondent for MLex in San Francisco, where he moved in 2020 after working in our Brussels bureau. Before joining MLex, he reported on EU politics as the Financial Times’ Nico Colchester Fellow in Brussels. Michael has a degree in International Relations and Politics from the University of Cambridge, and a degree in History and French from University College London and Paris IV Sorbonne.

Discover MLex

Stay on top of global regulatory developments

Latest News